Doximity rolls out a no-cost AI scribe for every U.S. clinician
Clinical-network giant Doximity is giving its new ambient-scribe tool away for free, betting that scale will matter more than subscription revenue. More than 10 000 physicians used the beta version over the past year, generating millions of notes that helped refine the underlying model. CEO Jeff Tangney told STAT the goal is to “hand clinicians their evenings back,” and early adopters say chart-closure time has dropped by half. The rollout also includes complimentary onboarding for free and charitable clinics, a move analysts at HLTH say could pressure rivals that charge per user. Physician-burnout researchers note that administrative load now rivals clinical fatigue as a driver of turnover, so a widely accessible scribe could move the needle on retention. Doximity hints that premium analytics—rather than basic dictation—may become its eventual revenue play, echoing the freemium path it took with telehealth dialing. Competitors such as Nuance and Abridge still price per seat, setting up a potential pricing showdown at the annual HIMSS conference this fall. If uptake mirrors the company’s telehealth boom during the pandemic, millions of encounters could be documented by algorithm before year-end, without a single licensing fee.
Ultromics secures $55 million to scale AI cardiac-ultrasound software
Oxford spin-out Ultromics closed a hefty Series C round to expand EchoGo®, its FDA-cleared algorithm that spots hidden heart-failure phenotypes on standard echos. Peer-reviewed data show the model detects HFpEF and cardiac amyloidosis up to 74 percent more accurately than manual reads, and reimbursement under Medicare’s AI-NTAP pathway has already spurred adoption. The fresh capital, investors told Yahoo Finance, will push the software into community echo labs where most scans occur. More than 430 000 studies have run through EchoGo® so far, and real-time reports drop seamlessly into existing PACS, according to coverage in AuntMinnie. Cardiologists point out that nearly two-thirds of U.S. heart-failure cases remain undiagnosed until hospitalisation, so earlier echo insights could curb readmissions. Ultromics also plans CE-mark submissions, eyeing rapid entry into EU markets where echo capacity is even more concentrated in secondary care. Executives say a cloud-first architecture lets small clinics run analyses on commodity laptops, lowering the bar for adoption. With total funding now north of $100 million, the company aims to be the AI layer that magnet vendors can’t ignore.
England’s first AI-run physio clinic halves back-pain waiting times
A 12-week pilot at Cambridgeshire Community Services Trust used Flok Health, an app that triages and coaches musculoskeletal patients with video-based AI, and cut overall MSK queues by 44 percent. More than 2 500 people completed same-day virtual assessments that would otherwise have required face-to-face appointments, freeing 856 clinician hours each month, the trust told Digital Health. Patient-reported outcomes on pain, mobility, and mood all improved, and fewer than 2 percent of users needed an in-person follow-up, according to data later posted on the NHS site. The pilot tackled one of the NHS’s biggest bottlenecks, lower-back pain, where waits can stretch beyond 18 weeks in some regions. Clinicians said the AI’s decision tree reliably flagged red-flag symptoms, easing safety concerns about remote triage. A patient-feedback loop asked users to film movements weekly, letting algorithms fine-tune exercise intensity in real time. National leaders are now evaluating cost-effectiveness data ahead of a wider rollout, while unions seek guarantees that digitally excluded patients will not be overlooked.
Everlab raises US$10 million to bring AI-driven preventive care to the masses
Melbourne start-up Everlab landed a seed round led by Left Lane Capital to expand its membership service that pairs full-body MRI, DEXA, ECG, and continuous glucose data with large-language-model “health agents.” The platform interprets more than a million biomarkers per member and sends personalised action plans nudging diet, exercise, and sleep. Tens of thousands are on the wait-list despite a hefty upfront fee; co-founder Veronica Ng told StartupDaily scale should bring the price below AU$1 200 within two years. Early results shared with Yahoo Finance show one in four users receive abnormal findings and more than one-third improve modifiable biomarkers at six-month follow-up. Clinicians advising the company say bundling high-resolution imaging with continuous monitoring could catch silent cancers and metabolic drift years earlier than annual physicals. Everlab is developing an API so external providers can plug the AI dashboard into existing patient portals, smoothing fragmentation. The founders hope to open clinics in New Zealand and Singapore next year, pitching themselves as a subscription pathway to “longevity mainstream.” Ethicists, meanwhile, warn of widening health-equity gaps if AI-powered prevention remains paywalled, setting the stage for policy debate as the model scales.
Image: PD
© 2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.